Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)
Vogler, Mary A., Teppler, Hedy, Gelman, Rebecca, Valentine, Fred, Lederman, Michael M., Pomerantz, Roger J., Pollard, Richard B., Cherng, Deborah Weng, Gonzalez, Charles J., Squires, Kathleen E., FranVolume:
36
Language:
english
Journal:
JAIDS Journal of Acquired Immune Deficiency Syndromes
DOI:
10.1097/00126334-200405010-00005
Date:
May, 2004
File:
PDF, 243 KB
english, 2004
File converter
More search results
More benefits 
